Recent advances in nonalcoholic fatty liver disease metabolomics

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations

Abstract

The clinical phenotypes of nonalcoholic fatty liver disease (NAFLD) encompass from simple steatosis to nonalcoholic steatohepatitis (NASH) with varying degrees of fibrosis or cirrhosis. Liver biopsy has been the standard to diagnose NASH. However, there has been strong need for precise and accurate noninvasive tests because of invasiveness and sampling variability of biopsy. Metabolomics has drawn attention as a promising diagnostic methodology in the field of NAFLD, particularly to unravel metabolic alterations which plays relevant roles in the progression of NASH. There have been numerous metabolomics researches to find new biomarker of NASH in the last decade, fueled by the recent advances in the metabolomics methodology. This review briefly covers recent research advances on the lipidomics, amino acids and bile acid metabolomics regarding continuing attempts to discover relevant biomarkers for NASH.

Original languageEnglish
Pages (from-to)553-559
Number of pages7
JournalClinical and molecular hepatology
Volume27
Issue number4
DOIs
StatePublished - Oct 2021

Bibliographical note

Funding Information:
This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (Grant no. 2018R1A5A2025286), the Research Supporting Program of the Korean Association for the Study of the Liver (Grant no. KASL2018-01) and the Technology Innovation Program (or Industrial Strategic Technology Development Program-Bioindustry Strategic Technology Development Program) (Grant no. 2013712)

Funding Information:
funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea).

Publisher Copyright:
© 2021 by Korean Association for the Study of the Liver.

Keywords

  • Amino acids
  • Bile acids and salts
  • Fatty liver
  • Lipids
  • Phenotype

Fingerprint

Dive into the research topics of 'Recent advances in nonalcoholic fatty liver disease metabolomics'. Together they form a unique fingerprint.

Cite this